Insulin, medium long-acting and short-acting or ultrashort-acting (in combination)

Generic name
Insulin, medium long-acting and short-acting or ultrashort-acting (in combination)
Brand name
ATC Code
A10AD01
Compare …

Insulin, medium long-acting and short-acting or ultrashort-acting (in combination)

Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Pharmacokinetics in children

No information

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Diabetes mellitus, insulin-dependent
  • Subcutaneous
    • 1 month up to 18 years

      • Dosage dependent on the blood sugar levels

      • Treatment by or after consulting a paediatric specialist (paediatric endocrinologist) who has experience of using insulins.

Renal impaiment in children > 3 months

The insulin requirement may be decreased in cases of reduced renal function. The dosage is adjusted depending on the blood glucose measurements in this case.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects

No information is present at this moment.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions

No information available on specific warnings and precautions in children.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

INSULINS AND ANALOGUES

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

Insulins and analogues for injection, fast-acting
A10AB01
A10AB04
Insulins and analogues for injection, intermediate-acting
A10AC01
Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting
A10AD06
Insulins and analogues for injection, long-acting
A10AE

References

  1. Rademaker C.M.A. et al, Geneesmiddelen-Formularium voor Kinderen, 2007
  2. Sanofi-Aventis Deutschland GmbH, SmPC Insuman Comb (EU/1/97/030/038-039) 17-05-2016, www.geneesmiddeleninformatiebank.nl
  3. Eli Lilly Nederland B.V, SmPC Humuline (RVG 14894) 01-01-2016, www.geneesmiddeleninformatiebank.nl
  4. Eli Lilly Nederland B.V, SmPC Humalog Mix (EU/1/96/007/005) 14-03-2016, www.geneesmiddeleninformatiebank.nl
  5. Novo Nordisk A/S, SmPC Novomix (EU/1/00/142/004-005) 04-02-2016, www.geneesmiddeleninformatiebank.nl
  6. Novo Nordisk A/S, SmPC Mixtard (EU/1/02/231/001-002;036) 17-03-2016, www.geneesmiddeleninformatiebank.nl
  7. Novo Nordisk A/S, SPC Actraphane (EU/1/02/229/001-002;036) 12/02/2016, www.geneesmiddeleninformatiebank.nl

Changes

Therapeutic Drug Monitoring


Overdose